Evidence map›Paper›PMID 25276283›Full record

ArticleWorld journal of hepatology2014

Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma.

Masako Shomura, Tatehiro Kagawa, Koichi Shiraishi, Shunji Hirose, Yoshitaka Arase, Jun Koizumi, Tetsuya Mine

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Masako ShomuraMasako Shomura, Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa 2591193, Japan.
Tatehiro KagawaMasako Shomura, Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa 2591193, Japan.
Koichi ShiraishiMasako Shomura, Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa 2591193, Japan.
Shunji HiroseMasako Shomura, Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa 2591193, Japan.
Yoshitaka AraseMasako Shomura, Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa 2591193, Japan.
Jun KoizumiMasako Shomura, Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa 2591193, Japan.
Tetsuya MineMasako Shomura, Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa 2591193, Japan.
Tokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo study the relationship between adverse events (AEs), efficacy, and nursing intervention for sorafenib therapy in patients with hepatocellular carcinoma (HCC).

methodsWe enrolled 37 consecutive patients with advanced HCC who received sorafenib therapy. Relationships among baseline characteristics as well as AE occurrence and tumor response, overall survival (OS), and treatment duration were analyzed. The nursing intervention program consisted of education regarding self-monitoring and AEs management, and telephone follow-up was provided once in 1-2 wk.

resultsA total of 37 patients were enrolled in the study, comprising 30 males (81%) with a median age of 71 years. The disease control rate at 3 mo was 41%, and the median OS and treatment duration were 259 and 108 d, respectively. Nursing intervention was given to 24 patients (65%). Every patient exhibited some kinds of AEs, but no patients experienced G4 AEs. Frequently observed AEs > G2 included anorexia (57%), skin toxicity (57%), and fatigue (54%). Factors significantly associated with longer OS in multivariate analysis demonstrated that age ≤ 70 years, presence of > G2 skin toxicity, and absence of > G2 hypoalbuminemia. The disease control rate in patients with > G2 skin toxicity was 13/20 (65%), which was significantly higher compared with that in patients with no or G1 skin toxicity. Multivariate analysis revealed that nursing intervention and > G2 skin toxicity were independent significant predictors for longer treatment duration.

conclusionSkin toxicity was associated with favorable outcomes with sorafenib therapy for advanced HCC. Nursing intervention contributed to better adherence, which may improve the efficacy of sorafenib.

Indexed as

Drug toxicityHepatocellular carcinomaMolecular targeted therapyNursing interventionSurrogate marker

Identifiers

PMID25276283
PMCPMC4179146
OpenAlexW2109910805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.